Targeted therapy and immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (stage C) that cannot be removed with surgery or cured with other treatments.
- You have never received any treatment for your liver cancer before.
- Your liver is working well enough (no fluid in the belly, no dangerous bleeding, no confusion, and your blood tests are within safe limits).
- You are in fairly good overall health (able to care for yourself and do light activity).
- You do not have HIV, a history of organ transplant, or active bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.